NASDAQ : BLLN

BillionToOne, Inc.

$93.39 USD

$1.74 (1.9%)

Volume
1.41M
Average Volume
713.38K
Market Capitalization
$4.3B
P/E Ratio
181.48
Dividend Yield
0.00%
Price Target
$127.50
Year High
$140.21
Year Low
$61.96
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$10.92
Company Overview

NASDAQ

Oguzhan Atay

Medical - Diagnostics & Research

Healthcare

BLLN

713

US

USD

https://www.billiontoone.com

(650) 460-2551

090168105

0002070849

Liquidity Metrics

0.29

10.92

10.58

9.40

0.00

Sales & Valuation

$305.11M

12.12

8.48

152.94

0.61

Profitability

$0.0637

$7.45M

7.11%

8.51%

7.55%

3.60%

P/E Metrics

181.48

0.04

0.04

Analyst Price Target & Rating

$127.50

$130.00

$125.00

Sell

2/5

4 Analysts

-26.75%

Financial Health Scores

14.46

7/9

$566.98M

$700.73M

$195.11M

$30.22M

Key Metrics (TTM)

$3.82B

10.78

93.52

10.92

7.55%

5.43%

0.60%

0.67%

$11.66

100 days

Company Executives
Name Title
David Tsao Co-Founder, President, Chief Technology Officer & Director
John D. Lister Chief Administrative Officer
Thomas Lynch Chief Compliance Officer, General Counsel & Secretary
Nancy Johnson Senior Vice President of Sales & Commercial Operations
Oguzhan Atay Co-Founder, Chairman & Chief Executive Officer
Ross Taylor Jr. Chief Financial Officer
Shan Riku Sakakibara Chief Product Officer
Jaclyn Vice President of Marketing
Vaghar Haghiri Senior Director of People Operations
Jean Hayden Vice President of Business Operations & Chief of Staff
Poll Results

No votes yet today — be the first to share your view!

About BillionToOne, Inc. (NASDAQ:BLLN) Stock

BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that ena ... bles continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.

BillionToOne: A Softer Quarter After Heightened Expectations

2026-08-07 14:41:56

BillionToOne experienced a sharp post-earnings sell-off despite maintaining full-year guidance and strong year-over-year revenue growth. Second quarter results showed slowing sequential growth, softer average selling prices, and significant margin compression versus Q1. The company trades at ~10x sales, a premium to May levels, with the growth story intact but near-term valuation less attractive.

BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to Say

2026-08-05 21:01:13

While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Billiontoone Q2 Earnings Call Highlights

2026-08-05 19:05:05

Billiontoone NASDAQ: BLLN reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses. The molecular diagnostics company also posted positive operating income and free cash flow while reiterating its full-year revenue outlook.

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

2026-08-05 16:05:00

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the second quarter ended June 30, 2026 and reiterated guidance for full year 2026.

BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar

2026-07-20 09:00:00

Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne to advance Northstar's role in guiding real treatment decisions MENLO PARK, Calif., July 20, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Ethan Dmitrovsky, MD, one of the most accomplished and influential physician leaders in oncology, as Chief Medical Officer, Oncology.

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-07-15 08:05:00

MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, August 5, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.

A BillionToOne Insider Sold 801 Shares as Revenue Jumped 84%

2026-07-12 19:56:36

According to a Form 4 filing, a BillionToOne executive sold 801 shares of Class A Common Stock at $124.91 per share for a total transaction value of $100,053 on July 1, 2026. The disposition reduced the insider's direct Class A common equity holdings by 4% in this transaction.

Tom Gardner's Five Stocks for the Long Term: Big Diversification, AI Research, and Caution

2026-07-08 11:57:08

Tom Gardner makes the case for fifty-stock portfolios and AI-powered research, then names five companies to consider owning for the next five-plus years.

Frequently Asked Questions

What is the current BillionToOne, Inc. (BLLN) stock price?

BillionToOne, Inc.(NASDAQ:BLLN) stock price is $93.39 in the last trading session. During the trading session, BLLN stock reached the peak price of $140.21 while $61.96 was the lowest point it dropped to. The percentage change in BLLN stock occurred in the recent session was 1.9% while the dollar amount for the price change in BLLN stock was $1.74.

BLLN's industry and sector of operation?

The NASDAQ listed BLLN is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.

Who are the executives of BLLN?

David Tsao | Co-Founder, President, Chief Technology Officer & Director
John D. Lister | Chief Administrative Officer
Thomas Lynch | Chief Compliance Officer, General Counsel & Secretary
Nancy Johnson | Senior Vice President of Sales & Commercial Operations
Oguzhan Atay | Co-Founder, Chairman & Chief Executive Officer

How many employees does BLLN have?

Number of BLLN employees currently stands at 713. BLLN operates from 1035 O’Brien Drive, Menlo Park, CA 94025, US.

Link for BLLN official website?

Official Website of BLLN is: https://www.billiontoone.com

How do I contact BLLN?

BLLN could be contacted at phone #(650) 460-2551 and can also be accessed through its website. BLLN operates from 1035 O’Brien Drive, Menlo Park, CA 94025, US.

How many shares of BLLN are traded daily?

The average number of BLLN shares traded daily for last 3 months was 713.38K.

What is the market cap of BLLN currently?

The market value of BLLN currently stands at $4.3B with its latest stock price at $93.39